Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid and Radiotherapy in Breast Cancer Bone Metastases
NCT00172029Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2003
- Primary completion
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of zoledronic acid in bone metastases (2 arms), sponsored by Novartis. Primary endpoint: Percentage of patients showing complete response in bone pain palliation without having any analgesic treatment at Week 24. Started Apr 2003; status: completed.
02
Drugs
zoledronic acid
03
Conditions
bone metastases
Beyond the preview
Go deeper on NCT00172029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00172029.